Cargando…

Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation

AIMS: Transcatheter treatment of heart valve disease is well established today. However, for the treatment of tricuspid regurgitation (TR), no effective catheter-based approach is available. Herein, we report the first human case description of transcatheter treatment of severe TR in a 79-year-old p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauten, Alexander, Ferrari, Markus, Hekmat, Khosro, Pfeifer, Ruediger, Dannberg, Gudrun, Ragoschke-Schumm, Andreas, Figulla, Hans R.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094550/
https://www.ncbi.nlm.nih.gov/pubmed/21300731
http://dx.doi.org/10.1093/eurheartj/ehr028
_version_ 1782203580161196032
author Lauten, Alexander
Ferrari, Markus
Hekmat, Khosro
Pfeifer, Ruediger
Dannberg, Gudrun
Ragoschke-Schumm, Andreas
Figulla, Hans R.
author_facet Lauten, Alexander
Ferrari, Markus
Hekmat, Khosro
Pfeifer, Ruediger
Dannberg, Gudrun
Ragoschke-Schumm, Andreas
Figulla, Hans R.
author_sort Lauten, Alexander
collection PubMed
description AIMS: Transcatheter treatment of heart valve disease is well established today. However, for the treatment of tricuspid regurgitation (TR), no effective catheter-based approach is available. Herein, we report the first human case description of transcatheter treatment of severe TR in a 79-year-old patient with venous congestion and associated non-cardiac diseases. In this patient, surgical treatment had been declined and pharmacological therapy had been ineffective. After ex vivo and animal studies, the treatment of TR was performed by percutaneous caval valve implantation. METHODS AND RESULTS: In a transcatheter approach through the right femoral vein, a custom-made self-expanding heart valve was implanted into the inferior vena cava (IVC). The device was anchored in the IVC at the cavoatrial junction with the level of the valve aligned immediately above the hepatic inflow and protruding into the right atrium. After deployment, excellent valve function was observed resulting in a marked reduction in caval pressure and an abolition of the ventricular wave in the IVC. Sequential echocardiographic exams over a follow-up period of 8 weeks confirmed continuous device function without paravalvular leakage or remaining venous regurgitation. The patient experienced improved physical capacity and was able to resume off-bed activities. There was no recurrence of right heart failure during follow-up and a partial reduction of ascites. The patient was discharged from hospital into a rehabilitation programme. CONCLUSION: Transcatheter treatment of severe TR by caval valve implantation is feasible resulting in an immediate abolition of IVC regurgitation and mid-term clinical improvement. Thus, in selected non-surgical patients, caval valve implantation may become a therapeutic option to treat venous regurgitation and improve associated non-cardiac diseases. Further confirmatory experience with longer follow-up is required to evaluate the long-term clinical benefit of the procedure as well as potential deleterious effects.
format Text
id pubmed-3094550
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-30945502011-05-16 Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation Lauten, Alexander Ferrari, Markus Hekmat, Khosro Pfeifer, Ruediger Dannberg, Gudrun Ragoschke-Schumm, Andreas Figulla, Hans R. Eur Heart J Fasttrack Clinical AIMS: Transcatheter treatment of heart valve disease is well established today. However, for the treatment of tricuspid regurgitation (TR), no effective catheter-based approach is available. Herein, we report the first human case description of transcatheter treatment of severe TR in a 79-year-old patient with venous congestion and associated non-cardiac diseases. In this patient, surgical treatment had been declined and pharmacological therapy had been ineffective. After ex vivo and animal studies, the treatment of TR was performed by percutaneous caval valve implantation. METHODS AND RESULTS: In a transcatheter approach through the right femoral vein, a custom-made self-expanding heart valve was implanted into the inferior vena cava (IVC). The device was anchored in the IVC at the cavoatrial junction with the level of the valve aligned immediately above the hepatic inflow and protruding into the right atrium. After deployment, excellent valve function was observed resulting in a marked reduction in caval pressure and an abolition of the ventricular wave in the IVC. Sequential echocardiographic exams over a follow-up period of 8 weeks confirmed continuous device function without paravalvular leakage or remaining venous regurgitation. The patient experienced improved physical capacity and was able to resume off-bed activities. There was no recurrence of right heart failure during follow-up and a partial reduction of ascites. The patient was discharged from hospital into a rehabilitation programme. CONCLUSION: Transcatheter treatment of severe TR by caval valve implantation is feasible resulting in an immediate abolition of IVC regurgitation and mid-term clinical improvement. Thus, in selected non-surgical patients, caval valve implantation may become a therapeutic option to treat venous regurgitation and improve associated non-cardiac diseases. Further confirmatory experience with longer follow-up is required to evaluate the long-term clinical benefit of the procedure as well as potential deleterious effects. Oxford University Press 2011-05 2011-02-07 /pmc/articles/PMC3094550/ /pubmed/21300731 http://dx.doi.org/10.1093/eurheartj/ehr028 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2011. For permissions please email: journals.permissions@oup.com. http://creativecommons.org/licenses/by-nc/2.5/ The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Fasttrack Clinical
Lauten, Alexander
Ferrari, Markus
Hekmat, Khosro
Pfeifer, Ruediger
Dannberg, Gudrun
Ragoschke-Schumm, Andreas
Figulla, Hans R.
Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
title Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
title_full Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
title_fullStr Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
title_full_unstemmed Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
title_short Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
title_sort heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
topic Fasttrack Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094550/
https://www.ncbi.nlm.nih.gov/pubmed/21300731
http://dx.doi.org/10.1093/eurheartj/ehr028
work_keys_str_mv AT lautenalexander heterotopictranscathetertricuspidvalveimplantationfirstinmanapplicationofanovelapproachtotricuspidregurgitation
AT ferrarimarkus heterotopictranscathetertricuspidvalveimplantationfirstinmanapplicationofanovelapproachtotricuspidregurgitation
AT hekmatkhosro heterotopictranscathetertricuspidvalveimplantationfirstinmanapplicationofanovelapproachtotricuspidregurgitation
AT pfeiferruediger heterotopictranscathetertricuspidvalveimplantationfirstinmanapplicationofanovelapproachtotricuspidregurgitation
AT dannberggudrun heterotopictranscathetertricuspidvalveimplantationfirstinmanapplicationofanovelapproachtotricuspidregurgitation
AT ragoschkeschummandreas heterotopictranscathetertricuspidvalveimplantationfirstinmanapplicationofanovelapproachtotricuspidregurgitation
AT figullahansr heterotopictranscathetertricuspidvalveimplantationfirstinmanapplicationofanovelapproachtotricuspidregurgitation